Inclusion Criteria

Inclusion criteria

- Signed written informed consent for biological analysis (all pts)

- Signed written informed consent for enrolment (pts with KRAS wild type)

- Male or female aged > or = 18 years

- Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

- KRAS evaluation availability with wild-type result

- Metastatic CRC not suitable for curative-intent resection

- Availability of tumour samples (or able and willing to provide tumour sample) and
blood for biological analysis

- Presence of at least one lesion measurable unidimensionally by computed tomography
(CT) scan or magnetic resonance imaging (MRI). (index lesion(s) must not lie within
an irradiated area)

- Eastern cooperative oncology group-performance status (ECOG-PS) <2

Exclusion criteria

- Brain metastasis (known or suspected)

- Previous chemotherapy for metastatic CRC (any). Adjuvant therapy is allowed if the
chemotherapy treatment free interval is > 6 months

- Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
entry

- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
indicated in the study protocol

- Any investigational agent(s) within 4 weeks prior to entry

- Previous exposure to HER-axis -pathway targeting therapy

- Leucocytes <3.0 x 109/L and neutrophils <1.5 x 109/L, platelets <100 x 109/L, and
hemoglobin <9 g/dL

- Bilirubin level either normal or >1.5 x ULN

- ASAT and ALAT >2.5 x ULN (>5 x ULN if liver metastasis are present)

- Serum creatinine >1.5 x ULN

- Clinically relevant coronary artery disease or a history of a myocardial infarction
within the last 12 months

- Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Pre-existing neuropathy > grade 1

- Known grade 3 or 4 allergic reaction to any of the components of the treatment

- Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ
of the cervix. (Pts with a previous malignancy but without evidence of disease for >
or equal 5 years will be allowed to enter the trial)

- Pregnancy or lactation

- Inadequate contraception (male or female pts) if of childbearing or procreational
potential

- Known drug abuse/ alcohol abuse

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent